
Total medical devices industry venture financing deals in December 2020 worth $896.64m were announced in the US, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 24.5% over the previous month and a rise of 9.4% when compared with the last 12-month average of $819.88m.
The US held a 55.1% share of the global medical devices industry venture financing deal value that totalled $1.63bn in December 2020.
In terms of deal activity, the US recorded 41 deals during December 2020, marking an increase of 28.1% over the previous month and a drop of 25.5% over the 12-month average.
The US medical devices industry venture financing deals in December 2020: Top deals
The top five medical devices industry venture financing deals accounted for 61.3% of the overall value during December 2020.
The combined value of the top five medical devices venture financing deals stood at $550m, against the overall value of $896.64m recorded for the month.
The top five medical devices industry deals of December 2020 tracked by GlobalData were:
1) Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings and T Rowe Price Associates’ $200m venture financing of Tempus Labs
2) The $150m venture financing of Singlera Genomics by CICC Kai Tak Fund, DETONG Capital Partners, FutureX Skyline Capital, Huamei International, Linden Asset Management, Prosperico Ventures, Proxima Ventures, Shanghai Free Trade Zone Fund Tao Capital, Shanghai Furong Investment, Shenzhen Green Pine Capital Partners and Wuxi Financial Investment
3) 5AM Venture Management, Arboretum Ventures, CrimsoNox Capital, EDBI, Forth Management, Jazz Venture Partners, Novartis, Pilot House Ventures Group, Quad Investment Management, Sarissa Capital Management, Shanda Group, SoftBank Vision Fund II and Temasek Holdings (Private)’s $80m venture financing of Pear Therapeutics
4) The $80m venture financing of 23andMe by NewView Capital and Sequoia Capital Operations
5) General Catalyst Partners, John Doerr and Mosaic Health Solutions’ venture financing of Well Dot for $40m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.